Harbour BioMed and BioMap Co-found MegaStream TechBio, a Next-Gen AI-Powered Complex Biologics Drug Discovery Company

Recently,BioMapandHarbour BioMedJointly announced that both partieswill be establishedA multi-level, long-term comprehensive strategic partnership.

According to the Strategic Cooperation Framework，The two parties will jointly establish a new type of company targeting the global marketAIPipeline R&D Company—MegaStream TechBio。

The company will integrate “exclusive big data×Exclusive Large Language Model×Large Innovative Pipeline Portfolio"，Building a new generation of intelligent dry-wet closed-loop experimental platform andPersonalized,Centered on multimodal, multi-attribute generative large modelsAIR&D Engine.

Focusing on major unmet clinical needs in cardiovascular, renal, anti-aging, and oncology areas, withFirst-in-Class（FIC）andBest-in-Class（BIC）as the core benchmark, develop next-generation frontier complex macromolecular drugs with global competitiveness, and systematically advance differentiated innovative pipelines into clinical stages, dedicated toTo become a global leader in complex macromoleculesAI Benchmark Enterprise in Drug Development。

Harbour BioMed will serve as the lead initiator, forMegaStreamOpen its globally unique fully human antibody platform, extensive target biology expertise, and global clinical development advantages; BioMap will serve as a co-initiator, providing the underlyingAITechnology empowerment, model engineering support, and intelligent R&D capabilities to accelerate the company's rapid advancementPipeline R&D Progress.

MegaStreamThe initial pipeline consists of the two parties' previous collaborativeAIDrug Development Projects and Newly InitiatedAIJointly constituted by the native pipeline R&D projects.

Both initiating parties shall be entitled to potential upfront payments, success milestones, and royalty shares in accordance with industry practice.

Meanwhile,MegaStream The core management team will be jointly formed by senior executives from multinational pharmaceutical companies and top experts in the field of artificial intelligence, with relevant personnel gradually taking their positions.

AsMegaStream TechBioJoint Initiator，Harbour BioMed and BioMap to Join Forces in Advancing Three Core Strategic Initiatives：

I. Establish a Globally Leading ExclusiveAIDDInfrastructurePlatform, Defining the Underlying Engineering Paradigm for Next-Generation Complex Macromolecules

Both parties willMegaStreamBuilding a globally leadingAIDriving Complex Macromolecular DrugsAIDDInfrastructureplatform. This platform will be built upon BioMap’s leading foundational large model platform for life sciencesxTrimo, andHarbour BioMed's ExclusiveHarbour Mice^®The massive amount of high-quality data accumulated by the fully human antibody platform.

In this powerful collaboration, BioMap will leverage its foundational large model capabilities in life sciences, combined with the high-quality, comprehensive data provided by Harbour BioMed, to conduct systematic, targeted training, optimization, and iteration, addressing the distinct characteristics of complex macromolecular drugs versus traditional general-purpose protein and antibody therapeutics.Forming a personalized and exclusive system with continuous self-evolution capabilitiesMegaStreamLargeModel. As the company's AI foundation,This model will be oriented towards next-generation multispecific antibodies,XDCConjugated Drugs, In VivoCAR-TInhalation/Deep optimization of complex macromolecules, such as oral biologics, delivering robust performance advantages and enabling an end-to-end workflow from sequence generation to developability optimization.AIDesign Capability.

II. Jointly Building Next-Generation IntelligenceHigh-Throughput Dry-Wet Closed-Loop Laboratory, forAINative Molecule High-Efficiency Validation and Continuous Data Accumulation Provide Closed-Loop Assurance

withMegaStreamLarge Language Modelas the foundation, both parties will leverage Harbour BioMed’s extensive proprietary experimental technology capabilities, as well as BioMapBioMap OSLeverage the system's advantages in high-throughput dry-wet closed-loop laboratory scheduling management, automated data analysis, data management, and model iteration to build a new generation of intelligent high-throughput dry-wet closed-loop laboratories.

To address the needs for model training and validation of various biological attribute parameters of complex macromolecular drugs, as well as the practical requirements for data accumulation and model iteration during drug development, this laboratory will establish a globally leading intelligent control hub and experimental capability system, achieving breakthroughs in four core capabilities: fully intelligent scheduling, high-performance experimental validation, automated acquisition and analysis of full-volume data, and efficientAIModeling and Model Evolution, Forming"Design-Construction-Test-Learning"Full-chain automated closed loop.

ThisAIUpon completion, the Native Intelligence Laboratory is expected to achieve higher efficiency compared to the previous generation of dry-wet closed-loop laboratories.500%The above will significantly accelerate the discovery and iteration pace of complex macromolecular drugs, driving a fundamental transformation in the R&D paradigm andAIThe continuous optimization of model capabilities provides strong support. Meanwhile, the laboratory will increase data accumulation efficiency by more than10times, expected to generate over in the next five years5PBhigh qualityAI-ReadyLife Science Data, DrivingAIThe model evolves rapidly and effectively.

3. Empowering the scaled-up development of a new generation of pipeline R&D portfolios,Achieve from“AIGenerate”to“Clinical Value”End-to-End Closed Loop

Both parties' firstAI+Biotechnology-drivenFirst-in-ClassPipeline R&D collaboration commenced in2021Year,and continuously empower key R&D stages, including property prediction, optimization, and generative design through AI, in more than 10 subsequent pipeline projects。

In the future, relying on the newly built next-generationAIComplex Macromolecule Drug R&D Platform,FIC/BICThe R&D capabilities of the pipeline will be significantly enhanced, for Harbour BioMed andMegaStreamConcurrent AdvancementHundreds of innovative pipeline projects provide solid support.

Recommended Reading